Reported Earlier: Novartis Receives European Commission Approval For Itvisma To Treat Children With 5q Spinal Muscular Atrophy

Novartis AG Sponsored ADR
Vanguard Ftseeuropean ETF

Novartis AG Sponsored ADR

NVS

0.00

Vanguard Ftseeuropean ETF

VGK

0.00

Novartis today announced that the European Commission (EC) has approved Itvisma® (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene.

With this approval, Itvisma becomes the first and only gene replacement therapy currently approved for this broad SMA population in the European Union.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.